


Supplementary Material


Safety and Tolerability of Active Immunotherapy Targeting α -Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study

Supplementary Figure 1. MRI volumetric analyses of marginal mean brain volumes (cm³) over time.




(Blue=15 µg PD03A, pink=75 µg PD03A, and green=placebo)

Supplementary Figure 2. Half maximum titers over time for the carrier protein keyhole limpet hemocyanin (KLH).




Supplementary Figure 3. Change in striatal binding ratios on DaT-SPECT (A) left striatum and (B) right striatum.

(A) Left striatal binding values



(B) Right striatal binding values



BL, Baseline; V11, visit 11 (Week 52)

Supplementary Table 1. Mean (\pm SD) MDS-UPDRS scores

	Baseline	Week 24	Week 52
MDS-UPDRS Part 1			
PD03A 15 μ g	1.9 (\pm 1.7)	1.8 (\pm 1.6)	1.4 (\pm 1.2)
PD03A 75 μ g	1.2 (\pm 1.5)	0.8 (\pm 1.4)	0.9 (\pm 1.8)
Placebo	1.7 (\pm 1.9)	2.6 (\pm 2.7)	1.8 (\pm 2.5)
MDS-UPDRS Part 2			
PD03A 15 μ g	4.9 (\pm 2.6)	5.2 (\pm 2.7)	6.9 (\pm 4.5)
PD03A 75 μ g	6.0 (\pm 3.7)	5.8 (\pm 4.6)	6.2 (\pm 4.8)
Placebo	6.6 (\pm 5.1)	6.6 (\pm 6.6)	7.4 (\pm 6.8)
MDS-UPDRS Part 3			
PD03A 15 μ g	19.3 (\pm 10.3)	21.2 (\pm 9.2)	22.3 (\pm 12.5)
PD03A 75 μ g	17.8 (\pm 11.2)	17.9 (\pm 11.4)	18.0 (\pm 12.1)
Placebo	18.9 (\pm 8.5)	19.1 (\pm 10.4)	20.1 (\pm 14.4)

Supplementary Table 2. Change of Levodopa equivalent dose (LED)

Treatment group	Mean \pm SD LED [mg]		
	Baseline	End of study	Change from baseline
PD03A 15 μ g	266 (\pm 192)	275 (\pm 201)	9 (\pm 30)
PD03A 75 μ g	361 (\pm 188)	444 (\pm 163)	83 (\pm 153)
Placebo	326 (\pm 169)	364 (\pm 229)	38 (\pm 90)